Zenosense, Inc.: Update on MIDS Medical Test Strip Development

VALENCIA, SPAIN, March 20, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Zenosense, Inc. (OTCQB: ZENO, "Zenosense", the "Company"), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection of heart attack at the Point of Care, is pleased to announce an update on test strip development by its MIDS Medical Ltd joint venture (“MML"). 

MML is in the process of prototyping an improved microfluidic detection area for its prospective MIDS Cardiac test strip.

The new prototyping aims to bring the assay beads into even closer contact with MML’s patented Hall effect sensor system. MML’s contracting company has produced a first set of microfluidic strips containing the new detection area. These incorporate a micro-machined, deepened section designed to maximize the trapping of the assay beads and to concentrate them directly on the sensor. This is expected to optimize fluid entrained bead detection sensitivity in the current design, improving on the sensitivity levels already achieved in the dry context.

This prototyping has been a highly challenging and time consuming process because of the microscopic scale MML’s contractor is working to.

These strips have now been flow tested with beads, and microscopically evaluated. This has revealed out of specification production issues causing some of the tested beads to collect in less than ideal areas for detection. A second iteration design is now in prototyping to attempt to address these production issues, incorporating additional modifications informed by MML’s flow testing and evaluation. MML is also exploring prototyping options that do not rely on micro-machining, as a back-up.

Once detection area prototyping and testing is satisfactorily completed, it is MML’s intention to expand the strip design and development to include assay-specific holding and reaction chambers, to largely complete the MIDS test strip configuration.

About Zenosense, Inc.

Zenosense Inc., through a joint-venture ownership in MIDS Medical Ltd., is primarily focused on the development of a cost-effective, hand-held Point of Care rapid cardiac diagnostic device, MIDS Cardiac. MIDS Medical applies patent-protected magnetic nanoparticle detection technology and a development team with world-class technical expertise. The MIDS Cardiac device and test strip is being designed to support a variety of rapid high sensitivity cardiac biomarker tests, with a focus on troponin I and T, to identify or discount Acute Myocardial Infarction with accuracy equal or superior to high sensitivity assays performed on laboratory analyzers. To find out more about Zenosense, visit www.zenosense.com

Forward-Looking Statements

Statements in this news release that are not statements of historical fact are forward-looking statements, which are subject to certain risks and uncertainties.  Forward-looking statements can often be identified by words such as "expects,” "intends,” "plans,” "may,” "could,” "should,” "anticipates,” "likely,” "believes" and words of similar import.  Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management.  Actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of factors that may or may not be foreseeable or within the reasonable control of the Company.  Readers are cautioned not to place undue reliance on such forward-looking statements.  Additional information on risks and other factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission, including without limitation the section entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed on filed on April 17, 2018, and in Company reports filed subsequently thereto.  Except as otherwise required by law, the Company disclaims any obligations or undertaking to publicly release any updates or revisions to any forward-looking statement contained in this news release to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Respective statements concerning the development of both MIDS Cardiac™ and other devices under development have been made based on information obtained from MIDS Medical Ltd. and Zenon Biosystem, which the Company believes to be accurate, but have not been independently verified.


Contact Data